In a phase II clinical trial, Landi et al. evaluated treatment with the targeted MET inhibitor crizotinib in an EGFR wild type NSCLC population of 26 patients with either MET amplification or METex14 mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.